CAYMAN CHEMICAL COMPANY, INCORPORATED
Ann Arbor, MI · Biotech · Private
Phosphorylated tau protein synthesis and assay kits for drug discovery in tauopathy diseases
caymanchem.com →- Grants
- $8.2M
- 10 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 22
- 5 granted · 17 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201720182019202020212022202320242025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Hyperphosphorylated tau aggregation kit to identify tauopathy risk factor | $224,852 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Development of a novel small molecule-based approach for accelerated fracture repair in the aging skeleton | $728,311 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Development of a novel small molecule-based approach for accelerated fracture repair in the aging skeleton | $1,478,369 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a novel small molecule-based approach for accelerated fracture repair in the aging skeleton | $750,058 | |
| Federal grant | Department of Health and Human Services · Phase II · Hyperphosphorylated tau aggregation kit to identify tauopathy risk factor | $778,104 | |
| Federal grant | Department of Health and Human Services · Phase II · Hyperphosphorylated tau aggregation kit to identify tauopathy risk factor | $1,512,583 | |
| Federal grant | Department of Health and Human Services · Phase II · Hyperphosphorylated tau aggregation kit to identify tauopathy risk factor | $734,479 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Small Molecule for Improved Dental Implant Osseointegration | $793,825 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Small Molecule for Improved Dental Implant Osseointegration | $906,661 | |
| Federal grant | Department of Health and Human Services · Phase I · Epigenetic Compounds Stimulating Dental Bone Repair | $306,868 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2089 | Eden Food International Inc. | — | $13M |
| 2090 | General Translation, Inc. | — | $2.4M |
| 2091 | CNS Pharmaceuticals, Inc. | — | $23M |
| 2092 | CAYMAN CHEMICAL COMPANY, INCORPORATED | — | — |
| 2093 | Kairos Pharma, LTD. | — | $4.2M |
| 2094 | MONON BIOVENTURES, LLC | — | — |
| 2095 | Sequor Pharamaceuticals LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- NOVEL HETEROCYCLES AS sPLA2-X INHIBITORSapplication
- Methods Of Synthesizing A Prostacyclin Analogapplication
- Methods Of Synthesizing A Prostacyclin Analoggranted
- Anti-citrullinated Hla Polypeptide Antibodies And Uses Thereofapplication
- Amine Salts Of A Prostacyclin Analoggranted
- Amine Salts of a Prostacyclin Analoggranted
- Chiral Compounds, Compositions, Products And Methods Employing Samegranted
- Methods of Synthesizing a Prostacyclin Analogapplication
- Multiheteroaryl Compounds As Inhibitors Of H-pgds And Their Use For Treating Prostaglandin D2 Mediated Diseasesgranted
- Skin Lightening Compositionsapplication
- Multiheteroaryl Compounds As Inhibitors Of H-pgds And Their Use For Treating Prostaglandin D2 Mediated Diseasesapplication
- Novel Heterocycles As SPLA2-X Inhibitorsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.